Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations. DermaChange Natural Shingles Treatment and Relief Cream.This article reviews the best shingles creams and offers a few options. Several creams and ointments are available in local drug stores or online for managing shingles. However, they can spread chickenpox to anyone who is unvaccinated or has never had chickenpox.Ī doctor may recommend antiviral medications, pain relievers, and over-the-counter (OTC) self-care creams to help ease the symptoms on the skin. A person who develops a shingles rash cannot spread shingles to another person. Most people only have one instance of shingles in their lifetime, but some may develop it more than once. Shingles occurs when the virus finds its way back to the skin. Following chickenpox, the varicella-zoster virus remains in the person’s nerves. Several large ongoing studies, of adequate duration, with clinically useful outcomes should provide more robust conclusions about both efficacy and harm.Anyone who has had chickenpox can develop shingles. Clinical experience also supports efficacy in some patients. This review found no evidence from good quality randomised controlled studies to support the use of topical lidocaine to treat neuropathic pain, although individual studies indicated that it was effective for relief of pain. Pooling multiple-dose studies across conditions demonstrated no clear evidence of an effect of lidocaine on the incidence of adverse events or withdrawals, but there were few events and the withdrawal phase of enriched enrolment designs is not suitable to assess the true impact of adverse events (very low quality evidence). In all but one study, third tier (very low quality) evidence indicated that lidocaine was better than placebo for some measure of pain relief. The two enriched enrolment, randomised withdrawal studies reported time to loss of efficacy. Three single-dose studies reported participants who were pain-free at a particular time point, or had a 2-point (of 10) reduction in pain intensity. Only one multiple-dose study reported our primary outcome of participants with ≥ 50% or ≥ 30% pain intensity reduction. We judged all of the studies at high risk of bias because of small size or incomplete outcome assessment, or both.There was no first or second tier evidence, and no pooling of data was possible for efficacy outcomes. Seven studies used multiple doses, with one to four-week treatment periods, and five used single applications. Two studies used enriched enrolment with randomised withdrawal. Most studies used a cross-over design, and two used a parallel-group design. Four different formulations were used: 5% medicated patch, 5% cream, 5% gel, and 8% spray. Six studies enrolled participants with moderate or severe postherpetic neuralgia, and the remaining studies enrolled different, or mixed, neuropathic pain conditions, including trigeminal neuralgia and postsurgical or post-traumatic neuralgia. We included 12 studies (508 participants) in comparisons with placebo or an active control. First tier evidence derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts at least 200 participants in the comparison, 8 to 12 weeks' duration, parallel design) second tier evidence from data that failed to meet one or more of these criteria and that we considered at some risk of bias but with adequate numbers in the comparison and third tier evidence from data involving small numbers of participants that we considered very likely to be biased or used outcomes of limited clinical utility, or both. We performed analysis using three tiers of evidence. Two review authors independently extracted efficacy and adverse event data, and examined issues of study quality. We included only full journal publication articles. Participants were adults aged 18 and over. We included randomised, double-blind studies of at least two weeks' duration comparing any formulation of topical lidocaine with placebo or another active treatment in chronic neuropathic pain. We also searched and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal to identify additional published or unpublished data. We searched CENTRAL, MEDLINE, and EMBASE from inception to 1 July 2014, together with the reference lists of retrieved papers and other reviews. To assess the analgesic efficacy of topical lidocaine for chronic neuropathic pain in adults, and to assess the associated adverse events. Lidocaine is a local anaesthetic that is sometimes used on the skin to treat neuropathic pain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |